Related Experiment Video

Updated: Dec 11, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.8K

New and emerging cardiovascular and antihypertensive drugs

Steven G Chrysant1, George S Chrysant2

  • 1Department of Cardiology, University of Oklahoma Health Sciences Center , Oklahoma City, OK, USA.

Expert Opinion on Drug Safety
|August 18, 2020
PubMed

Insights

New cardiovascular drugs show promise for managing hypertension and cardiovascular diseases (CVD). These emerging treatments offer novel mechanisms of action, potentially improving patient outcomes and reducing the socioeconomic burden of these widespread conditions.

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Drug Discovery

Background:

  • Hypertension and cardiovascular diseases (CVD) are leading causes of global disability and mortality.
  • Effective management is crucial to prevent severe cardiovascular and socioeconomic consequences.
  • Current treatments, while available, are not universally successful, highlighting the need for novel therapeutic agents.

Purpose of the Study:

  • To review newly released and emerging cardiovascular drugs for the management of hypertension and CVD.
  • To identify novel chemical entities with different mechanisms of action.
  • To assess the potential of these new drugs in clinical settings.

Main Methods:

  • A comprehensive Medline search was conducted for English-language literature published between 2010 and June 2020.
  • 62 relevant research papers detailing new cardiovascular drugs were retrieved and analyzed.
  • Focus on emerging drugs with potential applications in hypertension, CVD, heart failure, stroke, and type 2 diabetes mellitus.

Main Results:

  • Several new chemical entities (NCEs) demonstrate distinct mechanisms of action.
  • Preliminary studies indicate efficacy in treating hypertension, CVD, heart failure, stroke, and type 2 diabetes mellitus.
  • These NCEs show potential for use as monotherapy or in combination with existing cardiovascular medications.

Conclusions:

  • Emerging cardiovascular drugs offer new therapeutic options for hypertension and CVD.
  • These novel agents have shown promise in preliminary studies across various cardiovascular and metabolic conditions.
  • The development of these new drug classes may significantly reduce the socioeconomic impact of cardiovascular diseases.
Abstract

Keywords:
Hypertensioncardiovascular diseasediabetes mellitusheart failurenew drug

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.7K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.2K

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.0K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
759
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.1K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
433